Zentalis Pharmaceuticals (ZNTL) Change in Acquisitions & Divestments (2020 - 2026)

Zentalis Pharmaceuticals' Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $60.0 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments changed 0.0% year-over-year to $60.0 million; the TTM figure through Mar 2026 stood at $250.0 million (up 1047.89% YoY), while the FY2025 annual figure was $250.0 million, up 646.74% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $60.0 million, roughly flat from $60.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $198.5 million in Q2 2023, with the low at -$307.3 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $60.0 million (2025), against an average of $49.9 million.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments surged 251.25% in 2023, then slumped 407.25% in 2024.
• Zentalis Pharmaceuticals' Change in Acquisitions & Divestments stood at -$307.3 million in 2022, then surged by 117.61% to $54.1 million in 2023, then plunged by 407.25% to -$166.2 million in 2024, then jumped by 136.1% to $60.0 million in 2025, then changed by 0.0% to $60.0 million in 2026.
• Business Quant data shows ZNTL's Change in Acquisitions & Divestments at $60.0 million in Q1 2026, $60.0 million in Q4 2025, and $60.0 million in Q3 2025.